Compare ARK Genomic Revolution ETF (ARKG) vs Broadcom Inc (AVGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Broadcom Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.49, while Broadcom Inc trades at $419.47 (market cap $1.98T). The key difference: Broadcom Inc pays a 0.62% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Broadcom Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | AVGO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $481.57 |
52-Week Low | $24.02 | $289.60 |
Market Cap | — | $1.98T |
Enterprise Value | — | $2.02T |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Broadcom (AVGO) trades at $419.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong support at $412. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.44 exceeding the $2.40 estimate. Revenue grew to $63.89 billion in 2025, and net income surged to $23.13 billion, reflecting a 36.19% margin. Analysts maintain a strong buy consensus, with a $510.21 price target, citing AI-driven growth prospects.
The outlook for AVGO remains positive, driven by AI semiconductor demand and solid cash flow generation. However, high valuation multiples like a P/E of 69.23 pose risks if growth slows. Competitive pressures in the chip industry and macroeconomic volatility could challenge future performance, but institutional confidence and consistent earnings strength support a favorable investment case for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
